Navigation Links
Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Meniere's Disease
Date:12/11/2013

requency and improvement in tinnitus following a single administration compared to placebo. Otonomy has initiated the first of two pivotal clinical studies for OTO-104 in patients with Meniere's disease. OTO-104 has received Fast Track designation from the FDA.

About Meniere's Disease
Meniere's disease is a disorder of the inner ear characterized by acute episodes of vertigo, fluctuations in hearing, tinnitus and aural fullness. The underlying cause of Meniere's disease is unknown and there are currently no FDA-approved drug treatments. According to the National Institute on Deafness and Other Communication Disorders (NIDCD), there are more than 600,000 individuals diagnosed with Meniere's disease in the United States.

About Otonomy
Otonomy is a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the ear. Otonomy's proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic (IT) injection. Otonomy has three product candidates in development. OTO-201 is an antibiotic that is in Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. OTO-104 is a steroid that is in the first of two pivotal clinical studies for the treatment of patients with Meniere's disease. OTO-311 is an NMDA antagonist in development as a treatment for tinnitus. For more information please visit: www.otonomy.com.

Contact:

Media Inquiries
Canale Communications
Ian Stone
Account Director
619.849.5388
ian@canalecomm.com

Investor Inquiries
Westwicke Partners
Stefan Loren, Ph.D.
Managing Director
443.213.0507
sloren@westwicke.com

'/>"/>

SOURCE Otonomy, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Otonomy Completes $45.9 Million Series C Equity Financing
2. Otonomy Acquires Assets and Patent Rights for Tinnitus Program
3. CalHIPSO Enrolls Over 7,700 Providers in EHR Implementation Program, Hits Other Key Milestones After First Two Years
4. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
5. Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain
6. ROX Medical enrolls first patients in Ireland for CONTROL-HTN hypertension trial at Beaumont and Mater Private Hospitals
7. ROX Medical enrolls first UK patients in CONTROL-HTN hypertension trial at Eastbourne General Hospital
8. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
9. Barts Hospital, London enrolls first patients in ROX Medicals CONTROL-HTN resistant hypertension trial
10. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
11. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  NeuroSigma, Inc. (NeuroSigma), ... focused on commercialization of its non-invasive Monarch ... and neuropsychiatric disorders, today announced that enrollment has begun ... nerve stimulation (eTNS) as adjunctive therapy for the treatment ... being conducted at the Olive View-UCLA Medical Center in ...
(Date:7/22/2014)... York , July 22, 2014 ... Partnerschaft für umfassenden Schutz von Pharmazeuten ... Österreich    Equashield ( ... Transfersystemen (Closed System Transfer Devices, CSTDs) für gefährliche ... einen Vertriebshändler und Hersteller von medizinischen ...
(Date:7/21/2014)... McCord Research, Inc. was recently granted ... This patent describes a method for accelerating wound ... inventor, Dr. McCord, this method includes administering or ... composition of an effective amount of hydroxytyrosol and ... such that the administration of the combination reduces ...
Breaking Medicine Technology:Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 2Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 3Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 4Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome 5Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2
... well-tolerated with signs of durable,disease control in advanced ... /PRNewswire-FirstCall/ -- IDM,Pharma, Inc. today presented preliminary results ... trial (DC-MEL-202). The,results showed that UVIDEM was well ... response in patients with,progressive metastatic melanoma. , The ...
... trial presented at ENDO 2007 , ,- Regulatory approvals ... recruitment in Europe , ,MONTREAL, QUEBEC -- (MARKET WIRE) ... that 26-week data from,its first Phase 3 study testing ... ENDO, the 89th,annual meeting of the Endocrine Society. The ...
Cached Medicine Technology:IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 2IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 3IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 4IDM Pharma Presents Preliminary Results from Phase II UVIDEM,Melanoma Vaccine Clinical Trial 5Theratechnologies: TH9507 Phase 3 Clinical Update 2Theratechnologies: TH9507 Phase 3 Clinical Update 3
(Date:7/22/2014)... July 22, 2014 The Pennsylvania ... ) in the Philadelphia Court of ... punitive damages in cases alleging the medication caused ... Liebhard LLP reports. In an Order dated July ... plaintiffs’ request to certify the matter for an ...
(Date:7/22/2014)... The park is the heart of a community. ... made a recent investment in outdoor recreation and ... playground equipment from American Parks Company™. , The community ... is a 475-unit community that was established in the ... a tropical paradise with lush shade trees, green-edged walking ...
(Date:7/22/2014)... of the largest studies ever conducted into the genetic ... sites on chromosomes that harbor inherited genes tied to ... of researchers, now bring the total number of common ... Although these schizophrenia-associated genes aren,t specific enough to ... or will not develop the illness, researchers say they ...
(Date:7/22/2014)... school lacrosse players are facing an increasing number of ... study finds. Although the most common injuries are ... researchers report. They note a better understanding of why ... to protect student athletes. "Concern over concussions in ... learn more about these injuries," said study co-author Dawn ...
(Date:7/22/2014)... CarePoint Health is pleased to announce that Dr. ... the medical staff at Bayonne Medical Center. The election marks ... voted on by the physicians on staff. The office of ... to the administration at Bayonne Medical Center. Dr. Levine is ... to make the Medical Center the best it can be ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 2Health News:Injuries on the Increase in High School Lacrosse, Study Shows 3Health News:Dr. Howard Levine Elected President of the Medical Staff at Bayonne Medical Center 2
... Medical Innovations, Inc. (Amex: IMA ), a ... solutions, announced today that it will attend the upcoming ... 15, 2009 at the Westin St. Francis Hotel in ... Jon Russell, Vice President, Finance, will attend. Mr. ...
... Corporation (Nasdaq: BPUR ) announced today that ... stating that NASDAQ has again suspended enforcement of its ... listing, thereby extending the Company,s time in which to ... to resume on Monday, April 20, 2009. The Company ...
... Executive with Proven Ability to Develop Companies into ... Growth OpportunitiesFORT LAUDERDALE, Fla., Dec. 30 eDiets.com, ... provider of convenient at-home diet, fitness and healthy ... the company,s new President and CEO, effective immediately. ...
... didn,t halt women,s risk of developing disease , , TUESDAY, ... the supposed cancer-fighting powers of vitamins C and E, ... don,t prevent the disease in women. , And another ... new study found. , , "Simply taking antioxidant supplements ...
... had cancer as well as idiopathic pulmonary fibrosis, study finds ... in a gene previously found to help protect the lungs ... some inherited cases of a lethal lung disease affecting older ... the SFTPA2 gene have been found in families ...
... of adults and 19 percent of children taking chemotherapy drugs ... dose or experienced other mistakes involving their medications, according to ... professor of pediatrics at the University of Massachusetts Medical School, ... Journal of Clinical Oncology . , "As cancer care ...
Cached Medicine News:Health News:Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 13, 2009 2Health News:Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance 2Health News:eDiets.com(R) Appoints Kevin N. McGrath as President and CEO 2Health News:eDiets.com(R) Appoints Kevin N. McGrath as President and CEO 3Health News:Vitamins Fail to Prevent Cancer: Study 2Health News:Vitamins Fail to Prevent Cancer: Study 3Health News:Gene Mutation Tied to Inherited Fatal Lung Disease 2Health News:Errors involving medications common in outpatient cancer treatment 2
... practical, comfortable chair for examination ... height is adjustable from 540 ... use of an independent foot ... through 360 and incorporates a ...
... Halogen HPX Streak Retinoscope ... handle and provides 40% ... conventional scopes and maintains ... which greatly enhances illumination ...
Sandown chair, with hydraulic lift, sliding headrest and armrests with glides. Black vinyl....
3.5v Halogen HPX Spot Retinoscope provides 40% more light output than conventional scopes and maintains a consistent output level which greatly enhances illumination and produces the sharpest retina...
Medicine Products: